Fetal tissue transplanation in Parkinson's disease

Current Opinion in Neurology

Volumn 11, Issue 4, 1998, Pages 341-349

  Tabbal, Samer ^a   Fahn, Stanley ^a,b   Frucht, Steven ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEUROTROPHIC FACTOR; SCAVENGER;

AGE; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FETAL TISSUE TRANSPLANTATION; HUMAN; MESENCEPHALON; MONOAMINE NERVE CELL; PARKINSON DISEASE; REVIEW; SUBSTANTIA NIGRA; CELL SURVIVAL; CLINICAL TRIAL; DONOR; GENETIC ENGINEERING; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT;

CELL SURVIVAL; CLINICAL TRIALS; FETAL TISSUE TRANSPLANTATION; GENETIC ENGINEERING; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; PARKINSON DISEASE; TISSUE DONORS;

EID: 0032135785     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199808000-00010     Document Type: Review

References (104)

1. Ehringer H, Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramine) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klin Wochenschr 1960; 38:1236-1239.
2. Lindvall O. Neural transplantation. Cell Transplantation 1995; 4:391-400.
3. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's diseases. Trends Neurosci 1996; 19:102-109.
4. Huffaker TK, Boss BD, Morgan AS, Neff NT, Strecker RE, Spence MS, Miao R. Xenogratting of fetal pig ventral mesencephalon corrects motor asymmetry in the rat model of Parkinson's disease. Exp Brain Research 1989; 77:329-336.
5. Pakzaban P, Isacson O. Neural xenotransplantation: reconstruction of neural circuitry across species barriers. Neuroscience 1994; 62:989-1001.
6. Galpern WG, Burns LH, Deacon TW, Dinsmore J, Isacson O. Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft recovery. Exp Neurol 1996; 140:1-13.
7. Lindvall O, Swale G, Widner H, Rothwell JC, Bjorklund A, Brooks D, et al. Evidence of long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35:172-180.
8. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJG, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after fetal transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332:1118-1124. This report describes rigorously the PET scan changes as well as the growth, the integration and the extent of reinnervation of grafts in a patient with Parkinson's disease who died 18 months post-transplant.
9. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek Qi JX, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 and 24 months after transplantation for Parkinson's disease. N Engl J Med 1992; 327:1549-1555.
10. Deacon T, Schumacher J, Dinsmore J, Thomas C, Palmer Prather, Kott S, et al. Histological evidence of fetal pig neural cell survival after transplantation into patient with Parkinson's disease. Nature Med 1997; 3:350-353. This article is the first reported fetal pig neural cell transplant in humans, introducing Schumacher's series of 12 patients (expected to be published soon).
11. Kordower JH, Rosenstein JM, Collier TJ, Burke MA, Chen EY, Li JM, Martel L, et al. Functional fetal nigral grafts in patient with Parkinson's disease: chemoanatomic, ultrastructural, metabolic studies. J Comp Neurol 1996; 370:203-230.
12. Spencer D, RobbinsR, Naftolin F, Marek KL, VollmerT, Leranth C, et al. Unilateral transplantation of human fetal mesencephalic tissue in the caudate nucleus of patients with Parkinson's disease. N Engl J Med 1992; 327:1541-1558.
13. Forno LS, De Lanney LE, Irwin I, Langston JW. Similarities and differences between MPTP-induced Parkinsonism and Parkinson's disease. Adv Neurol 1993; 60:600-608.
14. Jellinger KA. Pathology of Parkinson's disease changes other than the nigrostriatal pathway. Mol Chem Neuropath 1991; 14:153-197.
15. Das GB. Transplantation of embryonic neural tissue in the mammalian brain. Growth and differentiation of the embryonic brain in the cerebellum of neonate rats. J Life Sci 1974; 4:93-124.
16. Allen GS, Burns RS, Tulipan NB, Parker RA. Adrenal medullary transplantation to the caudate nucleus in Parkinson's disease. Initial results in 18 patients. Arch Neurol 1989; 46:487-491.
17. Bakay RAE. Preliminary report on adrenal medullary grafting from the American Association of Neurological Surgeons GRAFT project. Restorative Neurol Neurosci 1989; 1:160.
18. Goetz, CG, Stebbins GT 3rd, Klawans, Koller WC, Grossman RG, Bakay RA, Penn RD. United Parkinson Foundation Neural transplantation Registry (1991) United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplantation: presurgical, and 1 and 2 year follow-up. Neurology 1991; 41:1719-1722.
19. Freeman TB, Olanow CW. Fetal homotransplants [letter]. Arch Neurol 1990; 40:1529.
20. Lawson HW, Atrash HK, Saftlas AF, Koonin LM, Ramick M, Smith JC. Abortion Surveillance, United States, 1984-1985. Morbidity and Mortality Weekly Report 1988; 38:11-42.
21. Costantini LC, Lin L, Isacson O. Medical fetal ventral mesencephalon: a preferred source for dopamine neuron grafts. NeuroReport 1997; 8:2253-2257.
22. Purves D, Snider W, Voyvodic J. Trophic regulation of nerve cell morphology and innervation in the autonomic nervous system. Nature 1988; 336:123-128.
23. Pedersen EB, Poulson FR, Zimmer J, Finsen B. Prevention of mouse-rat xenograft rejection by a combination therapy of cyclosporine A, prednisolone and azathioprine. Exp Brain 1995; 106:181-186.
24. Pakzaban P, Deacon TW, Burns LH, Dinsmore J, Isacson O. A novel mode of immunosuppression of neural xenotransplants: masking of donor major histocompatibility complex class I enhances transplant survival in the CNS. Neuroscience 1995; 65:983-996.
25. Honey CR, Clarke DJ, Dallman MJ, Charlton HM. Human neural graft function in rats treated with anti-interleukin Il receptor antibody. NeuroReport 1991; 1:247-249.
26. Patience C, Takenchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nature Wed 1997; 3:282-286. This study demonstrates that domestic swine DNA contains multiple copies of a genome (pig endogenous retrovirus) that encodes C-type retrovirus. This type of virus can be produced by two porcine kidney cell lines, one of which (the PK-15 cell line) is shown to be able to infect cultured human (kidney 293 cell line), pig and mink cells. It is not known whether normal pig cells in vivo release pig endogenous retrovirus particles and whether such particles replicate in vivo in humans.
27. Miyazono M, Nowell PC, Finan JL, Lee VM-Y, Tronowski JQ. Long-term integration and neuronal differentiation of embryonal carcinoma (NTera-2) transplanted into the caudoputamen of nude mice. J Comp Neurol 1996; 376:603-613.
28. Kordower JH, Chen EY, Winkler C, Frickert R, Charles V, Messing A, et al. Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice: trophic and tropic effects in a rodent model of Huntington's disease. J Comp Neuro l1997; 387:96-113. This encyclopedic article includes the details of the preparation of EGF-responsive neural stem cells and their transplantation in Huntington disease rat-models as well as a detailed account of their electron microscopic appearance and immunohistochemistry properties. The neuroprotection of striatal neurons by trophic factors is briefly reviewed.
29. Freeman TB, Spence MS, Boss BD, Spector DH, Strecker RE, Olanow CW, Kordower JH. Development of dopaminergic neurons in the human substantia nigra. Exp Neurol 1991; 113:344-353.
30. Verney C, Zecevic N, Nikolic B, Alvarez C, Berger B. Early evidence of catecholaminergic cell groups in 5- and 6-week-old human embryos using tyrosine hydroxylase and dopamine-B-hydroxylase immunocytochemistry. Neurosci Lett 1991; 131:121-124.
31. Bjorklund A, Stenevi U, Schmidt RH, Dunnett SB, Gage FH. Intracerebral grafting of neuronal cell suspension. II. Survival and growth of nigral cell suspension implanted in different brain sites. Acta Physiol Scand 1983; 522:9-18.
32. Freeman TB, Sanberg PR, Nauert GM, Boss BD, Spector D, Olanow CW, Kordower JH. Influence of donor age on the survival of solid and suspension intraparenchymal human embryonic micrografts. Cell Transplant 1995; 4:141-154.
33. Pakkenberg B, Moller A, Gunderson HJ, Mouritzen Dam A, Pakkenberg H. The absolute number of nerve cells in substantia nigra of normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neuro Neurosurg Psychiatry 1991; 54:30-33.
34. Frodl EM, Duan WM, Sauer H, Kupsch, Brundin P. Human embryonic dopamine neurons xenografted to rat: effect of cryopreservation and varying regional source of donor cells on transplant survial and morphology. Brain Res 1994; 647:286-298.
35. Brundin P, Strecker RE, Widner H, Clarke DJ, Nilsson OG, Astedt B, et al. Human fetal dopamine neurons grafted in rat model of Partkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release. Exp Brain Res 1998; 70:192-208.
36. Sauer H, Brundin P. Effect of cool storage on survival and function of intrastriatal ventral mesencephalic grafts. Restorative Neurol Neurosci 1991; 2:123-135.
37. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathologic and clinical implications. N Engl J Med 1998; 318:876-880.
38. Lindvall O. Neural transplantation in Parkinson's disease. In: Functional Neural Transplantation. Dunnet SB, Bjorklund A (editors): New York: Raven Press: 1994. pp. 103-137.
39. 18F] fluorodopa uptake in five grafted Parkinsonian patients. Ann Neurol 1995; 38:580-588.
40. Kopyov, OV, Jacques DS, Lieberman A, Duma CM, Rogers RL. Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. Exp Neurol 1997; 146:536-545.
41. Grabowska A, Lampson LA. Expression of class I and II major histocompatibility (MHC) antigens in the developing CNS. J Neural Transplant Plast 1992; 3:204-205.
42. Borlongan CV, Stahl CE, Cameron DF, Saporta S, Freeman TB, Cahill DW, Sanberg PR. CNS immunological modulation of neural graft rejection and survival. Neurol Res 1996; 18:297-304.
43. Sladek JR, Redmond DE, Collier TJ, Blount JP, Elsworth JD, Taylor JR, Roth RH. Fetal dopamine neural grafts: extended reversal of methylphenyltetrahydropyridine-induced parkinsonism in primates. Prog Brain Res 1998; 78:497-506.
44. Kordower JH, Styren S, Clarke M, Dekosky ST, Olanow CW, Freeman TB. Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant 1997; 6:213-219. Numerous inflammatory cells were identified 18-19 months post-transplantation within the surviving graft site at autopsy of a patient (case 2) who received cyclosporin for 6 months post-transplantation. Prior to death, the patient had a sustained clinical improvement and a progressive increase in flurodopa uptake between 6 and 12 months after cessation of cyclosporin. The clinical implications of this inflammatory reaction on the long-term survival and function of the graft remains unclear. It is conceivable that it may be detrimental (e.g. slow rejection, limitation of reinnervation of host targets) or beneficial (e.g. increased expression of neurotrophins induced by inflammatory mediators).
45. Freed CR, Trojanowski JQ, Galvin JE, Rosenstein JM, Breeze RE, Greene PE, et al. Embryonic dopamine cells cultured as strands show long term survival without immunosuppression in a patient with advanced Parkinson's disease. Soc Neurosci Abstr 1997; 23:1682.
46. Widner H, Terrud J, Rechcrona S, Snow B, Gustavii B, Bjorklund A, et al. Bilateral fetal mescencephalic grafting in two patients with parkinsonism induced by MPTP. N Engl J Med 1992; 327:1556-1563.
47. Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV et al. Bilateral fetal nigral transplantation into the postocommissural putamen in Parkinson's disease. Ann Neurol 1995; 38:379-388.
48. Hoffer BJ, Leenders KL, Young D, Gerhardt G, Zerbe GO, Bygdeman M, et al. Eighteen-month course of two patients with grafts of fetal dopamine neurons for severe Parkinson's disease. Exp Neurol 1992; 118:243-252.
49. Nikkhah, G, Cunningham MG, Jodicke A, Knappe U, Bjorklund A. Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral suspensions in rat Parkinson's model. Brain Res 1994; 663:133-143.
50. Lindvall O. Neural transplantation: a hope for patient with Parkinson's disease. Neuro Report 1997; 8:R3-R10. This 'minireview' objectively highlights conclusions that can be drawn from the completed clinical trials. It also addresses critical issues that may optimize the design of future trials.
51. Lapchak PA, Gash DM, Collins F, Hilt D, Miller PJ, Araujo DM. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): Preclinical development and application to the treatment of Parkinson's disease. Exp Neurol 1997; 145:309-321.
52. Hou JGG, Lin LFH, Mytilineou C. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1 -methyl-4-phenylpyridinium. J Neurochem 1996; 66:74-82.
53. Rosenblad C, Martinez-Serrano A, Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 1997; 82:129-137.
54. Lapchak PA, Miller PJ, Collins F, Jiao S. Glial cell line-derived neurotrophic factor attenuates behavioral deficit and regulates nigrostriatal dopaminergic and peptidergic markers in 6 hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience 1997; 78:61-72. This report demonstrates that, in 6-OHDA-lesioned rats, GDNF given intranigrally or intraventricularly reverses the apomorphine-induced rotational behavior and the decreased nigral (but not striatal) tyrosine hydroxylase activity/dopamine levels. These effects are suggested to be due in part to peptidergic markers changes (striatal dynorphine A increase) involving the direct basal ganglia pathway. It is suggested that intraventricular injections of GDNF (although less influential on the peptidergic markers than intranigral injections) may be useful for the treatment of Parkinson's disease.
55. Granholm A-C, Mott JL, Bowenkamp K, Eken S, Henry BJ, Lapchak PA et al. Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6 hydroxydopamine-lesioned striatum. Exp Brain Res 1997; 116:29-38.
56. Rosenblad C, Martinez-Serrano A, Bjorklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 1996; 75:979-985.
57. Sagra JI, Miura K, Bannai S. Maintenance of neuronal glutathione by glial cells. J Neurochem 1993; 61:1672-1676.
58. Nikkhah G, Bentlage C, Cunningham MG, Bjorklund A. Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model. J Neurosci 1994; 14:3449-3461.
59. Brooks DJ, Ibanez V, Swale GV, Quinn N, Lee AJ, Mathias CJ, Bannister R, et al. Differing pattern of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28:547-555.
60. Alexander GE, DeLong MR. Microstimulation of the primate neo striatum. II. Somatotopic organization of striatal microexcitable zones and their relation to neuronal response properties. J Neurophysiol 1985; 53:1417-1430.
61. Bankiewicz KS, Plunkett RJ, Jabobowitz DM, Kopin IJ, Oldfield EH. Fetal non-dopaminergic neural implants in Parkinsonian primates: histochemical and behavioral studies. J Neurosurg 1991; 74:97-101.
62. Mendez I, Sadi D, Hong M. Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplant. J Neurosci 1996; 16:72216-7227.
63. Nikkhah G, Cunningham MG, Cenci MA, McKay RD, Bjorklund A. Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. I. Evidence for anatomical reconstruction of the nigrostriatal pathway. J Neurosci 1995; 15:3548-3561.
64. Henderson C. Role of neurotrophic factors in neuronal development. Curr Opin Neurol 1996; 6:64-70.
65. Moller JC, Sautter J, Kupsch A. Potential of neutrotropic factors in therapy of Parkinson's disease. J Neural Transmission 1996; 48:103-112.
66. Knusel B, Winslow J, Rosenthal A, Burton L, Seid D, Nikolics K, Hefti F. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin-3. Proc Natl Acad Sci USA 1991; 88:961-965.
67. Sauer H, Fischer W, Nikkhah G, Wiegand SJ, Brundin P, Lindsay RM, Bjorklund A. Brain-derived neurotrophic factor enhances function rather than survival of intrastnatal dopamine cell-rich grafts. Brain Res 1993; 626:37-44.
68. Firm DM, Uhler TA, Short MP, Ezzedine ZD, Klagsburg M, Breakefield XO, Isacson O. Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. Neuroreport 1993; 4:367-370.
69. Altar CA, Boylan B, Hershenson S, Miller J, Wiegand SJ, Lindsay RM, Hyman C. Brain-derived neurotrophic factor augments rotational behaviour and nigrostriatal dopamine turnover in vivo. Proc Natl Acad Sci USA 1992; 89:11347-11351.
70. Yurek DM, Lu W, Hipkens S, Weigand SJ. BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons. Exp Neurol 1996; 137:105-118.
71. Krobert K, Lopez-Colberg I, Cunningham LA. Astrocytes promote or impair the survival and function of embryonic ventral mesencephalon co-grafts: effects of astrocytes age and expression of recombinant brain-derived neurotrophic factor. Exp Neuron 1997'; 145:511-523.
72. Olanow CW. An introduction to the free radical hypothesis of Parkinson's disease. Ann Neurol 1992; 32:S2-S9.
73. Dawson VL, Dawson TM. Free radicals and neuronal cell death. Cell Death different 1996; 3:71-78.
74. Lafon-Cazal M, Petri S, Calces M, Bockaert J. NMDA-dependent Superoxide production and neurotoxicity. Nature 1993; 364:535-537.
75. Troy CM, Derossi D, Prochiantz A, Greene LA, Shelanski ML. Down-regulation of Cu/Zn Superoxide dismutase leads to cell death via nitric oxide-peroxynitrite pathway. J Neurosci 1996; 16:253-261.
76. Nakao N, Frodt EM, Duan W-M, Winder H, Brundin P. Lazaroids improve the survival of grafted embryonic dopamine neurons. Proc Natl Acad Sci USA 1994; 91:12408-12412.
77. Nakao N, Frodl EM, Widner H, Carlson E, Eggerding TA, Epstein CJ, Brundin P. Over expressing Cu/Zn Superoxide dismutase enhances survival of transplanted neurons in rat model of Parkinson's disease. Nature Med 1995; 1:226-231.
78. Fridovich I. Superoxide radical and Superoxide dismutase. Annu Rev Biochem 1995; 64:97-112.
79. Barkats M, Nakao N, Grasbon-Frodl EM, Biland-Bleuel A, Revah F, Mallet J, Brundin P. Intrastriatal grafts of embryonic mesencephalic rat neurons genetically modified using adenovirus encoding human Cu/Zn Superoxide dimutase. Neuroscience 1997; 78:703-713.
80. Othberg A, Keep M, Brundin P. Tirilazad mesylate improves survival of rat and human embryonic mesencephalic neurons in vitro. Exp Neurol 1997; 147:498-502.
81. Frodl EM, Nakao N, Brundin P. Lazaroids improve the survival of cultured rat embryonic mesencephalic neurons. Neuroreport 1994; 5:2393-2396.
82. Bjorklund L, Spenger C, Stromberg I. Tirilazad mesylate increased dopaminergic neuronal survival in the in Oculo grafting model. Exp Neurol 1997; 148:324-333. This elegant experiment involves the transplantation of ventral mesencephalic tissue in the anterior chamber of the eye of rats. Enhanced dopamine neurons in the graft required tirilazad treatment at an intermediate dose during dissection as well as after transplantation (administered by intraocular repeated injections). Tirilazad lost its efficacy at excessive concentrations.
83. Taylor BM, Fleming WE, Benjamin CW, Wu Y, Mathews WR, Sun FF. The mechanism of cytoprotective action of lazaroids. I. Inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion. J Phar Exp Ther 1996; 276:1224-1231.
84. Andersson DK, Braughler JM, Hall ED. Effects of treatment with U-74006F on neurological recovery following experimental spinal cord injury. J Neurosurg 1988; 69:562-567.
85. Sanada T, Nakamure T, Nishimura MEA. Effects of U74006F on neurological function and brain edema after fluid percussion injury in rats. J Neurotrauma 1993; 10:65-71.
86. Lundberg C, Horellou P, Mallet J, Bjorklund A. Generation of dopaproducing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Exp Neurol 1996, 139:39-53.
87. Fischer LJ, Jinnah HA, Kale LC, Higgins GA, Gage FH. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce I-dopa. Neuron 1999; 6:371-380.
88. Jiao S, Gurevich V, Wolff JA. Long-term correction of rat model of Parkinson's disease by gene therapy. Nature 362:450-453.
89. Lundberg C, Martinez-Serrano A, Cattanea E, McKay RDG, Bjorklund A. Survival, integration, and differentiation of neural stem cell lines after transplantation to the adult rat striatum. Exp Neurol 1997; 145:342-360.
90. Federoff HJ, Geschwind MD, Geller AI, Kessler JA. Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. Proc Natl Acad Sci USA 1992; 89:1636-1640.
91. Le Gal La Salle G, Robert JJ, Berrard S, Ridoux V, Stratford-Perricaudet LD, Perricaudet M, Mallet J. An adenovirus for gene transfer into neurons and glia in the brain. Science 1993; 259:59-61.
92. Jiao SS, Williams P, Berg RK, Hodgman BA, Liu L, Repetto G, Wolff JA. Direct gene transfer into nonhuman primate myofibers in vivo. Hum Gene Ther 1992; 13:21-33.
93. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage F, et al. In vivo gene delivery and stable transduction of nondividing cells by lentiviral vector. Science 1996; 727:263-267.
94. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Current Top Microbiol Immunol 1992; 158:97-129.
95. Bankiewicz K, Leff SE, Nagy Dea, Jungles S, Rokovich J, Kaye S, et al. Practical Aspect of the development of ex vivo and in vivo gene therapy for Parkinson's disease. Exp Neurol 1997; 144:147-156. This article is an overview of our current knowledge and limitations in the development of gene therapy for Parkinson's disease.
96. Roy E. Gregoire F, Tardif P, Bedard J, Gravel C. Addition of adenoviral vectors to embryonic ventral mesencephalon cell suspensions used for striatal implantation into 6-hydroxydopamine-denervated rats induces detrimental immune responses [abstract]. Soc Neurosci Abstr 1995; 21:1980.
97. Lopez-Lozano JJ, Bravo G, Brera B, Millan I, Dargallo J, Salmean J, et al. Long-term improvement in patients with severe Parkinson's disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow-up in 10 patients. Clinica Puerta de Hierro Neural Transplant Group. J Neurosurg 1997; 86:931-942.
98. 18flurodopa uptake with maintained clinical improvement.
99. Perschanski M, Defer G, N'Guyen JP, Ricolfi F, Monfort JC, Remy P, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994; 117:487-499.
100. Folkerth RD, Druso R. Survival and proliferationof non-neuronal tissues with obstruction of cerebral ventricles in a parkinsonian patient treated with fetal allografts. Neurology 1996; 46:1219-1225.
101. Lindval O, Rehnerona S, Brundin P, Gustavii, Astedt B, Windner H, et al.: Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 1989, 46:615-631.
102. Henderson BT, Clough CG, Hughes RC, Hitchcock ER, Kenny BG. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. Arch Neurol 1991; 48:822-827.
103. Defer GL, Geny C, Ricolfi F, Fenelon G, Monfort JC, Remy P, et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 1996; 119:41-50.
104. •]). Interestingly, the grafted cells displayed no Lewy bodies, had appropriately no neuromelanin given their age, and expressed tyrosine hydroxylase mRNA comparable to normal nigral neurons. They induced no sprouting of host tyrosine hydroxylase immunoreactive fibers as seen with adrenal graft, suggesting that this effect is not as critical for clinical recovery as graft survival and reinnervation.